AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00426608 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: GSK561679 placebo tablets visually match the active GSK561679 tablets. Placebo to match Alprazolam is a hard gelatine capsule that visually matches active Alprazolam capsules.
Study NCT00426608 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK561679
Description: GSK561679 tablets will be available with dose strength of 50, 10 and 200 mg.
Study NCT04107493 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Portable Oxygen Cylinder
Description: A POC is a medical device that is indicated for patients who require supplemental oxygen, including COPD patients
Study NCT04107493 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mobi
Description: ResMed's variant of POC
Study NCT02686840 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sublingual misoprostol
Description: All patients will receive three doses of sublingual misoprostol every four hours The first dose of misoprostol 800 mcg will be administrated at the hospital. Then the patient will be observed for 1 hour for any immediate adverse reaction Clear instructions about the method and timing of second dose will be given upon sending home.~* Two doses of misoprostol 800 mcg each (four tablets of 200 mcg per dose).~* Paracetamol, eight hourly, will be provided as analgesic or antipyretic.~* A specimen bottle to collect the POC if passed out.~* Two pairs of disposable gloves.~* Pre-filled histopathological examination form to be sent to the laboratory together with the products of conception
Study NCT02686840 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vaginal misoprostol
Description: All patients will receive three doses of vaginal misoprostol every four hours The first dose of misoprostol 800 mcg will be administrated at the hospital. Then the patient will be observed for 1 hour for any immediate adverse reaction Clear instructions about the method and timing of second dose will be given upon sending home.~Paracetamol, eight hourly, will be provided as analgesic or antipyretic
Study NCT02999464 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Qigong
Description: The experimental group will be required to practice a total of 50 minutes of qigong training 3 times per week and for 16 weeks
Study NCT02999464 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fitness exercise
Description: Active control group will be required to practice a total of 50 minutes of fitness training 3 times per week and for 16 weeks
Study NCT00511563 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW876008 and GSK561679
Description: GW876008 and GSK561679
Study NCT04272359 — intervention group
Intervention type: DRUG
Intervention: Sulfa-zero: possible benefits of the treatment of new generation hypoglycaemic drugs compared to sulphonylureas
Description: Substitution of sulfonylureas with other classes of new hypoglycaemic drugs. In every group, it will be evaluated:~* efficacy in terms of glycometabolic compensation (glycemia, HbA1c, lipid profile);~* effects on BMI, blood pressure monitoring and hypoglycemic risk;~* changes in renal function and microalbuminuria;~* tolerability and side effects of the new therapeutic regimes;~* therapeutic adherence;~* post-prandial glycemic excursion, determined by a 6-point glycemic diary (pre- and 2h post-prandial glucose values) to be performed at home in the week before the scheduled follow-up visit;~* effects on chronic complications of diabetes and cardiovascular safety.
Study NCT02864225 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Scalp electrode,
Description: the parturient will be connected to the routine fetal Doppler and to the EUM. and When necessary to the scalp electrode will be connected. Tracings will be recorded simultaneously from all three devices until delivery. three separate outputs will be processed Output of the scalp electrode recording. Output of the fetal doppler. Output of the EUM. Three noncontinuous segments of 30 minutes each with two segments occurring during the first stage of labor and the third occurring during the second stage of labor, will be randomly picked from the scalp electrode recording with 3 matching segments in time from the EUM100pro and the fetal doppler
Study NCT02864225 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fetal doppler
Description: the parturient will be connected to the routine fetal Doppler and to the EUM. and When necessary to the scalp electrode will be connected. Tracings will be recorded simultaneously from all three devices until delivery. three separate outputs will be processed Output of the scalp electrode recording. Output of the fetal doppler. Output of the EUM. Three noncontinuous segments of 30 minutes each with two segments occurring during the first stage of labor and the third occurring during the second stage of labor, will be randomly picked from the scalp electrode recording with 3 matching segments in time from the EUM100pro and the fetal doppler
Study NCT02864225 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EUM
Description: the parturient will be connected to the routine fetal Doppler and to the EUM. and When necessary to the scalp electrode will be connected. Tracings will be recorded simultaneously from all three devices until delivery. three separate outputs will be processed Output of the scalp electrode recording. Output of the fetal doppler. Output of the EUM. Three noncontinuous segments of 30 minutes each with two segments occurring during the first stage of labor and the third occurring during the second stage of labor, will be randomly picked from the scalp electrode recording with 3 matching segments in time from the EUM100pro and the fetal doppler
Study NCT01166438 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum toxin A (Botox A®)
Description: A single intradetrusor injection of 100U botulinum toxin A in 10 mL plus 0.1 mL of indigo carmine administered during cytoscopy. Between 100 and 200ml of saline is instilled into the bladder prior to injection to allow adequate visualization of the entire bladder urothelium. The treating physician will inject a total of 10.1 mL of the masked substance into approximately 15 to 20 different detrusor muscle sites under direct visualization using disposable needles. Injections will be spread out to equally cover the posterior bladder wall and dome, but spare the bladder trigone and ureteral orifices.
Study NCT01166438 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Solifenacin 5mg
Description: Oral Solifenacin 5mg once a day for up to 6 months
Study NCT01166438 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Solifenacin 10mg
Description: Oral Solifenacin 10mg once a day for up to 4 months
Study NCT01166438 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trospium chloride
Description: Oral Trospium chloride XR 60mg once a day for up to 2 months
Study NCT00373672 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: armodafinil (Nuvigil)
Description: armodafinil (Nuvigil)150 mg qd
Study NCT00373672 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: identical in appearance to active comparator
Study NCT04096638 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB 11285
Description: SB 11285 2mg lyophilized powder for IV infusion
Study NCT01738620 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: psychological counseling
Study NCT01738620 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: prevention of sleep disorders in ICU
Study NCT00420199 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abatacept
Description: Vials (250 mg/vial), intravenous (IV), 10 mg/kg, monthly infusion , 12 months of treatment
Study NCT00420199 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous (IV) bags, IV, 0 mg, monthly infusion, 12 months of treatment
Study NCT03764839 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Perioperative Digital Behavioral Pian Medicine My Surgical Success
Description: The My Surgical Success website include 45 minutes of psychoeducation material developed and delivered by Beth Darnall, PhD. Viewers learn basic skills to improve regulation of pain-related distress. Treatment includes an app and a personalized plan for surgical success.
Study NCT03286751 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY900014
Description: Administered SC
Study NCT03286751 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Lispro
Description: Administered SC
Study NCT01649830 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Description: External beam radiation: 54.0 Gy in 27 - 30 fractions over 6 - 7 weeks.
Study NCT01649830 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: External beam radiation: 54.0 Gy in 27 - 30 fractions over 6 - 7 weeks.
Study NCT01649830 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: dosed at 200 mg/m2 (150 mg/m2 for the first cycle) daily for 5 consecutive days, repeated every 28 days.
Study NCT04244656 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CTX120
Description: CTX120 B-cell maturation antigen (BCMA)-directed T-cell immunotherapy comprised of allogeneic T cells genetically modified ex vivo using CRISPR-Cas9 gene editing components.
Study NCT00695630 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flumazenil
Description: 2 mL, 0.2 mg SM
Study NCT00695630 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 mL sterile saline SM
Study NCT01330316 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 201335
Description: BI 201335 for 24 weeks
Study NCT01330316 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PegIFN/RBV
Description: PegIFN/RBV for 48 weeks
Study NCT03088592 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Deep Brain Stimulation
Description: Subjects will have awake or asleep DBS surgery with STN or GPi placement. Microelectrode recordings will define the electrophysiological target prior to lead implantation. Cortical recordings will be done using µECoG grids (2.0 x 0.8 cm) placed over the cortex through the same burr hole used for lead implantation. Neural recordings will be made continuously throughout the procedure: before, during, and after DBS, and at all levels of anesthesia. A pulse generator will be connected and implanted either during the operation or within 7-10 days post-operatively. Subjects will be admitted overnight for observation with anticipated discharge the next morning. The researchers will also be collecting other routine data points (length of surgery, stereotactic accuracy, length of hospital stay, and post-operative complications).
Study NCT00338598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycine
Description: Glycine, 0.8 gr per kg given in two daily doses
Study NCT00338598 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT00003835 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Given IV
Study NCT00003835 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Given IV
Study NCT00003835 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Description: Given IV
Study NCT00003835 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT03769402 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Citric acid
Description: Citric acid ph1, 50% concentration solution
Study NCT03769402 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control Test
Description: Control group, xenograft was used to fill infrabony defects without treating bone surface
Study NCT00595504 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramelteon
Description: Two week supply of ramelteon 8mg/day first dispensed at baseline. New two week supply of study medication dispensed at each biweekly visit for 8 consecutive weeks.
Study NCT00595504 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two week supply of placebo tablets first dispensed at baseline. New two week supply of placebo dispensed at each biweekly visit for 8 consecutive weeks.
Study NCT03015506 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bread
Study NCT03015506 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bread
Study NCT04096638 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: 1680 mg every 4 weeks
Study NCT00169559 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GW590735
Description: 1µg to 20µg daily doses of GW590735
Study NCT00169559 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GW590735
Description: 1µg to 20µg daily doses of GW590735
Study NCT00169559 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: fenofibrate
Description: Marketed Drug
Study NCT03859258 — intervention group
Intervention type: DEVICE
Intervention: Transvaginal sonography
Description: Niche is assessed using TVS, SIS (cases only) and office hysteroscopy
Study NCT04367558 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Minimally invasive, in-office, RF reduction of the affected area
Description: Usage of RF needle to treat one or more of the affected areas
Study NCT01981525 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Treatment will be administered primarily on an outpatient basis. Patients will be instructed to take 500 mg metformin by mouth 1, 2 or 3 times a day or 1000 mg twice per day depending on dose level. Patients will receive metformin at level 1 dose for 2 weeks. If dose is tolerated, patient will receive level 2 dose for 2 weeks and if tolerated will escalate to level 3 dose, and if tolerated will escalate to level 4 dose. Metformin will be taken for 14 weeks.
Study NCT01538472 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Y Zevalin
Description: Starting dose: 0.4 mCi/kg by vein after Rituxan infusion on Day -14.
Study NCT01538472 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: In Zevalin
Description: Imaging dose: 5 mCi by vein following Rituxan infusion on Day -21.
Study NCT01538472 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituxan
Description: 250 mg/m2 by vein on Day -21 and on Day -14.~1000 mg/m2 by vein on Days +1 and +8.
Study NCT01538472 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCNU
Description: 300 mg/m2 by vein on Day -6.
Study NCT01538472 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VP -16
Description: 200 mg/m2 by vein every 12 hours on Days -5, -4, -3, and -2.
Study NCT01538472 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ara-C
Description: 200 mg/m2 by vein every 12 hours on Days -5, -4, -3,and -2.
Study NCT01538472 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: 140 mg/m2 by vein on Day -1.
Study NCT01538472 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem Cell Infusion
Description: Autologous stem cell infusion on Day 0.
Study NCT01538472 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: 5 mg/kg by vein daily starting Day 0 till recovery of granulocytes of 4.0 x 109/L.
Study NCT01291784 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: monoclonal antibody to TGF-beta
Description: starting dose of 1mg/kg intravenous over approximately 1 hour every 4 weeks for a total of 6 doses
Study NCT02992925 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DPT-IPV-Hib-High（Combined Vaccine）
Study NCT02992925 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DPT-IPV-Hib-Low（Combined Vaccine）
Study NCT02992925 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Hib vaccine
Study NCT02992925 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: DPT-IPV
Study NCT03074227 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Allogeneic faecal transplantation
Description: Patients will get bowel lavage through a nasoduodenal tube. This bowel lavage consists of 2-3 litres of macrogol electrolytes (Klean-Prep) solution. After that, patients will be treated with allogeneic faecal microbiota transplantation via the nasoduodenal tube.~Faeces will be collected from a donor.
Study NCT03074227 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Autologous faecal transplantation
Description: Patients will get bowel lavage through a nasoduodenal tube at our centre. This bowel lavage consists of 2-3 litres of macrogol electrolytes (Klean-Prep) solution. After that, patients will be treated with autologous faecal microbiota transplantation via the nasoduodenal tube.Faeces will be collected from the patient him/herself, in which their own faeces (autologous) will be used as a placebo.
Study NCT00948974 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Therapy
Description: Cognitive therapy (CT) highlights the identification and reappraisal of distorted or dysfunctional cognitions in the treatment of psychopathology. For example, socially anxious patients are taught to identify the thoughts and underlying beliefs that trigger strong emotional reactions (e.g., if I attempt to initiate a conversation I'll humiliate myself), and then replace these with more accurate, functional thoughts. There is a large body of research supporting the efficacy of CT for mood and anxiety disorders, and for social anxiety disorder in particular (Beck, 2005).
Study NCT00948974 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Acceptance and Commitment Therapy
Description: ACT does not attempt to modify cognitions directly, but rather seeks to foster a mindful acceptance of whatever thoughts or feelings arise, while still pursuing specific behavioral goals. For example, the individual would be taught simply to notice the thoughts as if from a distance without attempting to modify them, and initiate a conversation. Like other newer mindfulness and acceptance-based models of CBT, ACT also expands the traditional focus on symptom reduction to include an emphasis on broader life goals. The scientific literature on ACT has expanded rapidly over the past ten years. Recent reviews conclude that it appears to be at least as effective as CT, and may work at least in part via distinct treatment mechanisms (Powers, Zum Vörde Sive Vörding, \& Emmelkamp, 2009).
Study NCT01509417 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ad lib feedings after pyloromyotomy
Description: ad lib feedings after pyloromyotomy
Study NCT03996057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methenamine Hippurate 1000 MG
Description: Discussed in arm/group description
Study NCT03996057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vaginal estrogen
Description: Any form of low dose vaginal estrogen, whether ring, cream, tablet, or capsule. Depends on what patient is already using.
Study NCT01509417 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FLAP diet after pyloromyotomy
Description: FLAP diet after pyloromyotomy
Study NCT01509417 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: FLAP diet after pyloromyotomy
Description: FLAP diet after pyloromyotomy
Study NCT03996057 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vaginal estrogen
Description: Any form of low dose vaginal estrogen, whether ring, cream, tablet, or capsule. Depends on what patient is already using.
Study NCT03996057 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: D-mannose
Description: Powder or tablet, depending on what patient is already using.
Study NCT03996057 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: D-mannose
Description: Powder or tablet, depending on what patient is already using.
Study NCT02382406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Nab-paclitaxel 100 mg/m2 IV, D1, D8, D15 for 4 cycles (cycle = 21 days)
Study NCT02274389 — intervention group
Intervention type: DRUG
Intervention: No Intervention
Description: This is an observational study and participants did not receive any intervention in this study. Participants initiating bedaquiline (BDQ) treatment as decided by healthcare provider, will be prospectively observed.
Study NCT02505854 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic
Description: Hypocaloric diet associated with capsule containing 1billion UFC Bifidobacterium lactis and sache of maltodextrin
Study NCT01972529 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: avatrombopag (lower baseline platelet count)
Description: 60 mg avatrombopag (3 x 20 mg tablets)
Study NCT02505854 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Symbiotic
Description: Hypocaloric diet associated with capsule containing 1billion UFC Bifidobacterium lactis and sache of fructooligosaccharide
Study NCT02505854 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Hypocaloric diet associated with capsule containing 50g of gelatin and sache of maltodextrin
Study NCT04551885 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FT516
Description: Experimental Interventional Therapy
Study NCT04551885 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Monoclonal antibody
Study NCT04551885 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Lympho-conditioning agent